LAMIVUDINE, NEVIRAPINE, AND STAVUDINE
Pre-Launchlamivudine, nevirapine, and stavudine
NDAORALTABLET
Lifecycle
Pre-Launch
Clinical Trials
1
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing three nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV-1 infection treatment. The combination of lamivudine, stavudine, and nevirapine works by inhibiting viral reverse transcriptase to suppress HIV replication. This oral tablet formulation represents a simplified multi-drug regimen approach to antiretroviral therapy.
Pre-Launch
Pre-launch stage offers opportunities for launch team assembly including regulatory affairs, market access, and commercial strategy roles, though market size and penetration remain to be validated against established HIV regimens.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children
Started Dec 2006
44 enrolled
HIV Infections
Career Relevance
Working on this pre-launch HIV combination offers entry-level to mid-career professionals the opportunity to build a brand launch from regulatory approval through market introduction in a highly competitive therapeutic area. Career growth depends on successful regulatory approval and market penetration against established competitors; roles will evolve from launch planning to lifecycle management and market defense.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.